Sign In
Buy MNMD
$20.69
+0 (+0%)
At Close: Jun 18, 2026
Mind Medicine: No News = Good News
09:55am, Sunday, 10'th Nov 2024
Mind Medicine's share price has responded very strongly to a third quarter update that contained very little new information. The market appears to have moved to a bullish stance following confirmatio
Mind Medicine (MindMed) Inc. (MNMD) Q3 2024 Earnings Call Transcript
08:06pm, Thursday, 07'th Nov 2024
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Stephanie Fagan – Chief Corporate Affairs Officer Rob Barrow – Chief E
Mind Medicine: Two Pathways Created From One Pipeline Clinical Candidate
04:04pm, Monday, 04'th Nov 2024
Mind Medicine (MindMed) Inc. is advancing MM-120 for GAD with two phase 3 trials, VOYAGE and PANORAMA, starting in late 2024 and early 2025. MM-120 is also being tested for MDD in the phase 3 EMERGE s
Psychedelic Stocks: Focus On Their Cash
12:30pm, Thursday, 15'th Aug 2024
Jason Najum covers the psychedelic space and contextualizes recent news around the FDA, MDMA, PTSD, and Lykos Therapeutics. Why it may be a blessing in disguise for Cybin, COMPASS Pathways, and MindMe
Mind Medicine (MindMed) Inc. (MNMD) Q2 2024 Earnings Call Transcript
11:21am, Tuesday, 13'th Aug 2024
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD ) Q2 2024 Earnings Conference Call August 13, 2024 8:00 PM ET Company Participants Robert Barrow - CEO Daniel Karlin - CMO Reid Robison - Senior Principal Inv
MindMed readying Phase III trials for LSD therapy to treat anxiety
07:44am, Tuesday, 13'th Aug 2024
MindMed Inc. MNMD, -0.87% said Tuesday it's on track to launch Phase 3 clinical trials with up to 440 people starting later this year for its treatment of generalized anxiety disorder (GAD) through us
Pacific Defense Announces US Army CMFF Program Team
07:01am, Tuesday, 13'th Aug 2024
EL SEGUNDO, Calif.--(BUSINESS WIRE)--Pacific Defense, a leading provider of Modular Open Systems Approach (MOSA) products and mission solutions, announced their team to compete for the U.S. Army's CMO
FDA Rejection of MDMA Therapy Isn't End of Psychedelic-Drug Candidates
12:47pm, Monday, 12'th Aug 2024
The Food and Drug Administration rejected Lykos' application to treat PTSD with MDMA therapy. Atai, Compass Pathways, and MindMed are sliding in the wake of the decision.
Psychedelic drug contender stocks drop after FDA rejects MDMA treatment
12:12pm, Monday, 12'th Aug 2024
Shares of companies developing treatments based on psilocybin and other psychedelic drugs moved lower on Monday after the U.S. Food and Drug Administration rejected use of MDMA for post-traumatic stre
Mind Medicine (MindMed) Inc. Announces Proposed Public Offering
06:00am, Friday, 09'th Aug 2024
NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to
MindMed And Other Psychedelic Stocks Brace For FDA's Decision On MDMA Therapy
02:29pm, Wednesday, 07'th Aug 2024
The FDA's decision on MDMA therapy for PTSD is imminent, impacting MindMed investors and the psychedelic medicine industry. An FDA advisory committee voted against approving MDMA therapy, causing mark
3 Psychedelic Stocks to Ride to the Moon and Beyond
07:21am, Saturday, 06'th Jul 2024
The value of the psychedelic market is expected to approximately triple over the next few years. While not a large market in absolute terms, that growth potential will create many winning stocks.
FDA Favorites: 3 Biotech Stocks on the Verge of Major Approvals
02:13pm, Thursday, 04'th Jul 2024
The biotech industry has fallen on hard times over the last few years, no thanks to venture capital drying up, tighter regulatory conditions and the harsh reality of the post-pandemic healthcare envir
MindMed to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
07:00am, Friday, 21'st Jun 2024
NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to
MindMed Announces Constructive End-of-Phase 2 Meeting with U.S. FDA for MM120 in Generalized Anxiety Disorder (GAD)
07:00am, Thursday, 20'th Jun 2024
NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to
